No Data
No Data
The biopharmaceutical sector is showing strong momentum. Kelunbotai Bio (06990) rose 6.6%, and institutions pointed out that innovative drug companies are gradually approaching the breakeven point in terms of profit and loss.
Jinwu Financial News | The biopharmaceutical sector has shown strong performance, with Kexingbo Tai Bio (06990) up 6.6%, Kanno (02162) up 5.9%, Hutchmed (China) (00013) up 4.42%, and Innovent Bio (01801) up 3.81%. In terms of news, Zhongyin International Securities stated that the revenue growth of the innovative drugs sector is strong. Among the sectors, the best-performing sector is innovative drugs (Biotech), with an average revenue growth of 25.3%, mainly due to the positive medical insurance payment environment for innovative drugs and the authorized revenue obtained by some innovative drug companies through product overseas licensing.
Is Merck's BD supporting performance and stock price, and is it difficult to stop the upward valuation of Collenbotech Bio-B (06990) even with "returns"?
For stocks, if they can withstand the "unlocked big test" and the stock price remains relatively strong, the future trend will be much more market-oriented. Conversely, if the stock price falls sharply, it will be more difficult to regain popularity later. Now looking back, Kolonbotai undoubtedly belongs to the former.
Hong Kong Stock Exchange Announcement | Chinasoft Int'l and Huawei join hands to create a new chapter of digitalization in the electrical utilities industry.
Alibaba-W (09988) common stock is included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect; Core product Lucong Satuximab (sac-TMT) of Coronabio-B (06990) will announce research results at the European Oncology Conference in 2024.
[Brokerage Focus] Everbright Securities: Maintains a buy rating on Coronation Bio (06990), pointing out its rich pipeline and gradually emerging overseas value of ADC.
Jingu Financial News | Debang Securities released a research report, stating that the revenue of Coronbio Technology (06990) in the first half of 2024 was 1.383 billion RMB, with a growth rate of 32.2%. This growth is mainly due to the milestone payments and collaborative payments resulting from the cooperation agreement signed with Merck. The gross profit in the first half of the year reached 1.077 billion yuan, a year-on-year increase of 59.4%, and the net income was 0.31 billion yuan, compared with a loss of 31.13 million yuan in the same period last year. R&D expenses in the first half of the year were 0.652 billion RMB, a year-on-year increase of 33%. The bank expects to launch its core product in the Chinese market in the second half of 2024 or the first half of 2025.
Sichuan Kelun-Biotech Biopharmaceutical to Present Cancer Drug Trial Results At ESMO
KoLun Botai Biotechnology-B (06990.HK): The research results of its core product Lu Kang Sha TMT (sac-TMT) were announced at the European Oncology Conference in 2024.
Gelonghui, September 9th - Kolonbor Tech-B (06990.HK) announced that the company will announce the following research results of its anti-TROP2 ADC sacitrastuzumab tesirine (sac-TMT, formerly known as SKB264/MK-2870) at the 2024 European Society for Medical Oncology (ESMO) Conference in Barcelona, Spain, from September 13th to 17th, 2024: 1. The efficacy and safety of sacitrastuzumab tesirine (sac-TMT) combined with pembrolizumab (Keytruda) for the treatment of relapsed or metastatic cervical cancer (CC), will be announced locally.
No Data
No Data